3,0
7 de jan. de 2015
Funcionário(a) sigiloso(a)
Ex-funcionário(a)
Recomenda
Visão de mercado da empresa
Prós
Diversity in Oncology portfolio, very strong in oncology.
Contras
Its strength in oncology is due to its subsidiary: Genentech. It has no historical experience in oncology. While Genentech is open, dynamic, and innovative; Roche is stiff and very conservative...it could not make drug development by itself.